Catalyst OrthoScience Gains Funding to Support Shoulder System

Catalyst OrthoScience Archer CSR

Catalyst OrthoScience raised $12.3 million in an oversubscribed Series D financing round.

Thus far in 2021, Catalyst has:

Rebranded its product portfolio with the Archer family name,
Received FDA 510(k) clearance and began a limited launch for the Archer R1 Reverse Shoulder System and
Introduced its Archer 3D Targeting...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0